• Mycobacterium tuberculosis and the response of its host
• 34 min
  1. The genetic structure of Mycobacterium tuberculosis - insights into genome organisation and evolution of the causative agent of tuberculosis

  • Dr. Roland Brosch
• 36 min
  2. The pathogenesis of tuberculosis

  • Dr. William R. Bishai
• 57 min
  3. Immune response and rational development of vaccines and biomarkers

  • Prof. Dr. Stefan H. E. Kaufmann
• 38 min
  4. Molecular mechanisms of drug resistance in M. tuberculosis

  • Dr. Daniela Cirillo
• The epidemiology of tuberculosis
• 40 min
  5. The basic epidemiology of tuberculosis (TB)

  • Dr. David Dowdy
• 34 min
  6. Global epidemiology of TB

  • Dr. Philippe Glaziou
• 48 min
  7. Social determinants of tuberculosis

  • Dr. Knut Lönnroth
• The control of tuberculosis
• 46 min
  8. Treatment of tuberculosis

  • Dr. Jean-Pierre Zellweger
• 32 min
  9. The End TB Strategy towards TB elimination 1

  • Dr. Mario Raviglione
• 52 min
  10. The End TB Strategy towards TB elimination 2

  • Dr. Mario Raviglione
• 38 min
  11. Financing TB care and control

  • Dr. Christopher Fitzpatrick
  • Dr. Andrea Pantoja
• 27 min
  12. Tuberculosis and COVID-19

  • Prof. Giovanni Battista Migliori
• 36 min
  13. Multidrug resistant tuberculosis (MDR-TB): an update

  • Dr. Simon Tiberi
• 49 min
  14. Impact of HIV on tuberculosis in the developing world and how to manage it

  • Prof. Anthony D. Harries
• 33 min
  15. Reaching the missing millions through public-private mix (PPM) for TB prevention and care

  • Ms. Hannah Monica Dias
• 39 min
  16. TB in children

  • Prof. Ben J. Marais
• 30 min
  17. Community engagement in tuberculosis care

  • Ms. Lana Syed
• 29 min
  18. India: the epicentre of global TB control

  • Dr. Madhukar Pai
• 23 min
  19. Community engagement in TB care

  • Dr. Haileyesus Getahun
• Research and development for new approaches in the control of tuberculosis
• 21 min
  20. Development of new regimens for tuberculosis

  • Dr. Zhenkun Ma
• 35 min
  21. Development, testing and introduction of new diagnostic tools for tuberculosis

  • Dr. Mark Perkins
• 69 min
  22. Pharmacometrics in tuberculosis

  • Prof. Charles A. Peloquin
• 29 min
  23. Extrapulmonary tuberculosis

  • Dr. Scott Heysell
• 27 min
  24. The role of surgery in tuberculosis management

  • Dr. Richard Zaleskis
• Archived Lectures *These may not cover the latest advances in the field
• 28 min
  25. The development of current treatments for tuberculosis

  • Dr. Andrew Nunn
• 47 min
  26. The pathogenesis of tuberculosis

  • Dr. William R. Bishai
• 34 min
  27. Basics of tuberculosis epidemiology

  • Prof. Frank Cobelens
• 40 min
  28. Drug resistance in tuberculosis and its public health management

  • Dr. Paul Nunn
• 57 min
  29. The international approach to the control of tuberculosis

  • Dr. Mario Raviglione
• 35 min
  30. Public-private mix for TB care and control

  • Dr. Mukund Uplekar

Printable Handouts

PDF

Navigable Slide Index

1. Introduction
2. Outline
3. Importance of India in global TB control
4. 8.8 million incident cases of TB in 2010
5. India accounted for 25% of this TB burden
6. No country has more cases of TB than India
7. TB control in India: what has been accomplished?
8. TB control in India is the RNTCP responsibility
9. RNTCP: achievements
10. RNTCP has made the most of existing toolbox
11. TB control in India has been cost-effective
12. Challenges for TB control after DOTS scale-up
13. Very slow decline in TB incidence
14. What factors may explain this?
15. Threat of drug-resistant TB
16. What does "TDR-TB" really indicate?
17. Mismanagement of TB in India
18. RNTCP limited capacity to deal with MDR-TB
19. TB diagnostic practices in the private sector
20. WHO has warned against inaccurate TB tests
21. Widespread use of serological tests for TB
22. Survey: 17 of 22 use these antibody tests
23. Why inaccurate TB tests used in India?
24. Root causes for popularity of serology in India
25. Government of India banned TB serology tests
26. Treatment deviates from international standards
27. TB drugs are very available
28. Impact of TB mismanagement
29. A typical TB patient in India
30. New vision and goals for TB control
31. What is the new vision for TB control?
32. Raising the level of ambition: universal access
33. The RNTCP will pursue the following approaches
34. Universal access via improved, early diagnosis
35. Media campaign
36. Replacing bad with WHO-endorsed tests
37. Engaging to replace serology with WHO-tools
38. Improve notification of TB cases
39. For the new vision to succeed, India needs
40. How can India contribute to global TB control?
41. India's economic growth
42. India's progress in science
43. India's progress in communications
44. Success story with generic drugs and vaccines
45. India is poised to take the lead in TB diagnostics
46. Creating an ecosystem for innovation
47. India can also provide leadership in research
48. India's TB control will impact on global TB control
49. BRICS are now poised to provide new leadership
50. Thank you for listening

Topics Covered

• Importance of India in global TB control
• Burden of TB in India
• Challenges for TB control in India
• New vision and goals for TB control in India
• How can India contribute to global TB control?

Links

Series:

• Tuberculosis

Categories:

• Microbiology

Therapeutic Areas:

• Infectious Diseases
• Respiratory Diseases

Talk Citation

Publication History

• Published on February 28, 2013

Financial Disclosures

• Dr. Madhukar Pai has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.